WHO Drug Information Vol. 17, No. 2, 2003
(2003; 64 pages) View the PDF document
Table of Contents
Open this folder and view contentsGood Manufacturing Practices
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsSafety Issues
Open this folder and view contentsCurrent Topics
Open this folder and view contentsRegulatory and Safety Action
Open this folder and view contentsAspects of Quality Assurance
Close this folderRecent Publications and Sources of Information
View the documentInternational Travel & Health
View the documentAffordability of medicines
View the documentDrugs and money
View the documentABPI launches online clinical trials register
View the documentExpert Committee on Drug Dependence Report
View the documentBiomedical research in human subjects
View the documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
 

Expert Committee on Drug Dependence Report

The Thirty-third report presents recommendations from the Expert Committee on Drug Dependence which is responsible for reviewing information on dependence-producing drugs and assessing the need for international control by the UN Commission on Narcotic Drugs. It is important to balance the need for preventing diversion of therapeutic substances with abuse potential against the need to ensure access for therapeutic use. WHO has developed a formal procedure for its review of dependence-producing psychoactive substances which is described in the first part of the report.

This is followed by a critical review of five psychoactive substances (amfepramone, amineptine, buprenorphine, delta-9-tetrahydrocannabinol and tramadol). The report also discusses the substances that were pre-reviewed by the Committee, four of which (ketamine, zopiclone, butorphanol and khat) were recommended for critical review at a future meeting. The final section discusses the problems of the terminology used in reporting abuse-related adverse drug reactions and describes how confusion affects the reporting of adverse effects using as an example the selective serotonin reuptake inhibitors (SSRIs).

WHO Expert Committee on Drug Dependence. Thirtythird report. WHO Technical Report Series, No. 915 (2003). Available from: Marketing and Dissemination, World Health organization, 1211 Geneva 27, Switzerland. e-mail: bookorders@who.int

to previous section to next section
 

Last updated: May 3, 2013